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Abstract
Brain metastases are the most common cause of death in patients with meta-
static melanoma, and the RAF-MEK-ERK and PI3K-AKT signaling pathways
are key players in melanoma progression and drug resistance. The BRAF inhibi-
tor vemurafenib significantly improved overall survival. However, brain meta-
stases still limit the effectiveness of this therapy. In a series of patients, we
observed that treatment with vemurafenib resulted in substantial regression of
extracerebral metastases, but brain metastases developed. This study aimed to
identify factors that contribute to treatment resistance in brain metastases.
Matched brain and extracerebral metastases from melanoma patients had iden-
tical ERK, p-ERK, and AKT immunohistochemistry staining patterns, but there
was hyperactivation of AKT (p-AKT) and loss of PTEN expression in the brain
metastases. Mutation analysis revealed no differences in BRAF, NRAS, or KIT
mutation status in matched brain and extracerebral metastases. In contrast,
AKT, p-AKT, and PTEN expression was identical in monolayer cultures derived
from melanoma brain and extracerebral metastases. Furthermore, melanoma
cells stimulated by astrocyte-conditioned medium showed higher AKT activa-
tion and invasiveness than melanoma cells stimulated by fibroblast-conditioned
medium. Inhibition of PI3K-AKT signaling resensitized melanoma cells isolated
from a vemurafenib-resistant brain metastasis to vemurafenib. Brain-derived
factors appear to induce hyperactivation of the AKT survival pathway and to
promote the survival and drug resistance of melanoma cells in the brain. Thus,
inhibition of PI3K-AKT signaling shows potential for enhancing and/or
prolonging the antitumor effect of BRAF inhibitors or other anticancer agents
in melanoma brain metastases.
76 ª 2012 The Authors. Published by Blackwell Publishing Ltd. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
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Introduction
The prognosis for melanoma patients with distant metas-
tases is poor, with a median overall survival time of about
8 months [1], reflecting the failure of the chemotherapy
and immunotherapy regimens that were used in the past.
However, basic research has shown that the RAF-MEK-
ERK and PI3K-AKT signaling pathways are key players in
melanoma progression and drug resistance [2, 3]. A
recent phase III study showed that the BRAFV600E kinase
inhibitor vemurafenib induced partial or complete tumor
regression in 48% of patients with BRAFV600E-mutated
metastatic melanoma as compared with 5% of patients
treated with the classical chemotherapeutic agent dacarb-
azine [4]. Moreover, in a phase II trial of vemurafenib
with a long follow-up, the median overall survival was
approximately 16 months [5]. However, brain metastases
still limit the effectiveness of this therapy.
Brain metastases occur in over 70% of patients with
metastatic melanoma and are the most common cause of
death. The overall survival of melanoma patients with
brain metastases is generally very poor, with a median sur-
vival time of 5 months [6]. Current therapeutic options
include neurosurgery, radiosurgery, whole-brain radiation,
and chemotherapy. Patients treated with neuro- or radio-
surgery appear to have a longer median survival of about
9 months [6, 7]. Chemotherapeutic agents such as tem-
ozolomide that are used for treating primary brain tumors
are not effective for cerebral melanoma metastases [8].
Intriguingly, a recent phase 2 trial showed that immuno-
therapy with ipilimumab has some activity in melanoma
brain metastases, particularly when brain metastases are
small and asymptomatic [9]. Furthermore, recent and
ongoing clinical trials show clinical activity of BRAF inhib-
itors in patients with asymptomatic melanoma brain
metastases [10, 11]. However, effects of BRAF inhibitors
in melanoma brain metastases appear to be limited.
We observed in a series of patients that treatment with
the BRAF inhibitor vemurafenib yielded a substantial
response in extracerebral metastases, but brain metastases
developed. The aim of this study was thus to identify
factors that contribute to the relative treatment resistance
of brain metastases.
Materials and Methods
Isolation and culture of human cells
The use of human tissue was approved by the medical
ethics committee of the University of Tuebingen (Project
Number 017/2012BO2) and was performed in accordance
with the Principles of the Declaration of Helsinki. Cell
lines and melanoma cells from excised brain or extra-
cerebral metastases were isolated and cultured as
described previously [12–14]. Human fibroblasts were iso-
lated from human foreskin and cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS) [14]. Immortalized human fetal astrocytes
(SV-FHA) were kindly provided by Dr. Muruganandam
(Institute of Biological Sciences, National Research Coun-
cil of Canada) and were cultured in DMEM with FBS.
Stimulation with conditioned medium
To obtain conditioned medium, fibroblasts and astrocytes
were grown for 24 h in Roswell Park Memorial Insitute
(RPMI) without serum. The medium was collected and
frozen at 80°C until use. Prior to stimulation, mela-
noma cells were seeded at a density of 250,000 cells per
well in a six-well plate. The next day, conditioned media
from fibroblasts and astrocytes were added; RPMI with-
out serum was added to control cells. The cells were har-
vested and lysed after 1, 3, and 6 h of stimulation.
Signaling pathway inhibitors
Signaling pathway inhibitors included the BRAFV600E
kinase inhibitor, vemurafenib (Selleck), and the PI3K
inhibitor, GDC-0941 (Selleck, ICS International Clinical
Service GmbH, Mu¨nchen, Deutschland). Inhibitors were
dissolved in dimethylsulfoxide, and stored at 20°C.
Controls were incubated with culture medium or culture
medium and DMSO (Dimethylsulfoxid).
Immunohistochemistry
For immunohistochemistry, human tumor tissue was fixed
in 4% formalin and embedded in paraffin. The following
primary antibodies were used: anti-ERK, anti-phospho-
ERK (Thr202/Tyr204), anti-AKT, anti-phospho-AKT
(Thr308), anti-PTEN, anti-Melan-A (Cell Signaling Tech-
nology Inc., Beverley, MA), anti-CD14 (Cellmark, Medac,
Gothenburg, Sweden), anti-GFAP (Clone6F2), and anti-
HMB45 (DAKO, Hamburg, Germany). Specifically, Melan-A,
glial fibrillary acidic protein (GFAP), HMB45, and CD14
were detected using the UltraView Universal DAB Detec-
tion Kit, and the other antibodies were detected using the
UltraView Universal Alkaline Phosphatase Red Detection
Kit from Ventana (Tucson, AZ). Quantification and scor-
ing of blinded samples were done using LQ (Pathology),
AB (Neuropathology), and FM (Dermatopathology).
Matrigel cell invasion assay
Inserts (Corning Life Sciences, Amsterdam, the Nether-
lands) were coated with Matrigel (BD Biosciences,
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Heidelberg, Germany), and Z€uMel1 and Z€uMel1H mela-
noma cells were seeded onto the Matrigel matrix and fed
with DMEM without FBS. The lower chamber of the
transwell was filled with serum-free culture medium
(ctrl), fibroblast- or astrocyte-conditioned medium (cm).
After 24 h, the membrane was fixed and stained with
hematoxylin. The cells that had migrated to the bottom
surface of the membrane were counted.
Western blot
Western blot analysis was performed as described previ-
ously [15]. The following primary antibodies were used:
anti-ERK, anti-phospho-ERK (Thr202/Tyr204), anti-AKT,
anti-phospho-AKT (Thr308), anti-PTEN, and anti-Actin
(Cell Signaling, Beverley, MA). For quantification, Scion
Image was used to compare phospho-AKT/Actin from
the sample to phospho-AKT/Actin from the control. Cells
newly isolated from brain and extracerebral distant metas-
tases of melanoma patients were subjected to Western
blot analysis within 14 days.
Mutation analysis
For polymerase chain reaction (PCR) and sequencing, DNA
was isolated from patient samples by proteinase K digestion.
Subsequently, DNA was amplified with PCR using different
primer sets (Table S2). Direct DNA sequencing was
performed using the purified PCR products.
Growth assay
Growth assays were performed as described previously
[12, 15].
Apoptosis assay
The apoptosis assays were performed as described previ-
ously [12, 15]. Each histogram represents at least 10,000
individual events (measured cells).
Results
Clinical observations
Our repeated observation is that patients with metastatic
melanoma who are treated systemically with BRAF inhibi-
tors show remission of extracerebral metastases, but
development or progression of brain metastases. Here, we
describe the clinical courses of two patients who received
vemurafenib. Both patients had a complete remission of
extracerebral metastases, but also showed development of
new cerebral metastases.
Case report 1
In August 2010, a 49-year-old man with BRAFV600E-
mutated metastatic melanoma was enrolled into the
BRIM-3 trial receiving the BRAFV600E kinase inhibitor
vemurafenib. Computed tomography (CT) scans demon-
strated a partial remission of the axillary, mediastinal,
hilar, and lung metastases without evidence of brain
metastases. However, a CT scan of the brain on May
2011 revealed a cerebellar metastasis on the left side
(Fig. 1A and B) despite further regression of lymph node
and lung metastases (Fig. 1C and D). The cerebellar
metastasis was surgically removed, and therapy with
vemurafenib was continued. The last CT imaging (28
August 2012) showed complete remission (Fig. 1E and F)
(Table S1: Patient 1).
A B
C D
E F
Figure 1. Computed tomography (CT) scans before and during
treatment with vemurafenib (patient 1). (A) CT scan (August 2010)
before treatment: no cerebral metastases. (B) CT scan (May 2011)
during treatment: new cerebral metastasis. (C) CT scan (August 2010)
before treatment: hilar lymph node metastases. (D) CT scan (May
2011) during treatment: regression. (E) CT scan (August 2012) during
treatment: complete remission of extracerebral metastases. (F) CT
scan (August 2012) during treatment: no cerebral metastases.
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Case report 2
In June 2010, a 46-year-old man with BRAFV600E-
mutated metastatic melanoma was recruited into the
BRIM-3 trial receiving vemurafenib. After 4 months, the
CT imaging showed a complete response of lung, liver, and
lymph node metastases. In August 2011, the patient devel-
oped two brain metastases (Fig. 2A and B), although the
extracerebral metastases of the patient were in complete
remission (Fig. 2C–F). Vemurafenib was discontinued, and
therapy with ipilimumab (3 mg/kg body weight) was
started. Before the third cycle of ipilimumab treatment,
cerebral and leptomeningeal metastases were diagnosed
(Fig. 2G). Otherwise the other metastases of the patient
were in complete remission (Fig. 2H). Three months later,
the patient died as a result of brain metastases (Table S1:
Patient 2).
Five other patients being treated with vemurafenib for
metastatic melanoma developed new cerebral metastases,
whereas the extracerebral metastases continued to respond
to therapy (Table S1).
Histological and mutational analysis
AKT is predominantly activated in melanoma
brain metastases
As the RAF-MEK-ERK and PI3K-AKT signaling pathways
are thought to be key players in melanoma progression
and drug resistance, we performed immunohistochemical
analyses of cerebral metastases and of matched extra-
cerebral metastases from the same patients. All metastases
were synchronously collected from patients with stage IV
melanoma before initiating systemic treatment. The
melanocyte marker Melan-A and the signal transduction
molecules ERK, activated ERK (p-ERK), AKT, and acti-
vated AKT (p-AKT), and a major negative regulator of
the PI3K-AKT pathway, the phosphatase and tensin
homolog deleted from chromosome 10 (PTEN), were
analyzed. Immunohistochemical analysis (Fig. 3A–D)
showed that most cerebral and extracerebral metastases
were positive for ERK and AKT throughout the entire
tumor, while p-ERK was seen predominantly at the
tumor periphery. Interestingly, most cerebral metastases
were highly positive for activated AKT (p-AKT), whereas
extracerebral metastases, in particular lung and liver
metastases, present at the same time in the same patients
were weakly positive or negative for activated AKT
(Fig. 3C and D; Table 1). Moreover, the negative regula-
tor of the PI3K-AKT pathway, PTEN, was downregulated
in most brain metastases (Fig. 3E; Table 1). To determine
where the p-AKT signal comes from, two-color immunohis-
tochemical staining was performed. Figure 3F shows
colocalization of p-AKT with the melanocytic marker
A B
C D
E F
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Figure 2. Computed tomography (CT) scans before and after
treatment with vemurafenib (A–F) or ipilimumab (G and H) (patient
2). (A) CT scan (June 2010) before treatment: no cerebral
metastases. (B) CT scan (August 2011) after treatment: new
cerebral metastases. (C) CT scan (June 2010) before treatment:
pulmonary metastases. (D) CT scan (August 2011) after treatment:
complete remission. (E) CT scan (June 2010) before treatment: liver
metastases. (F) CT scan (August 2011) after treatment: complete
remission. (G) Magnetic resonance tomography (November 2011)
after treatment with ipilimumab: progression of brain metastases
with leptomeningeal metastases. (H) CT scan (November 2011)
after treatment with ipilimumab: complete remission of liver
metastases.
ª 2012 The Authors. Published by Blackwell Publishing Ltd. 79
H. Niessner et al. Hyperactivation of AKT in Melanoma Brain Metastases
HMB-45, indicating that in melanoma cells AKT is acti-
vated. Furthermore, we performed double immunohisto-
chemistry for p-AKT and GFAP, a marker for glial cells,
and for p-AKT and CD14, a monocyte/macrophage
marker. As shown in Figure 3G and H, p-AKT does not
colocalize with GFAP or CD14. Altogether, the immuno-
histochemical findings indicate that AKT is strongly acti-
vated in melanoma cells that have metastasized to the
brain.
BRAF, NRAS, and KIT mutation status is identical
in brain and extracerebral melanoma metastases
Mutational analysis of BRAF, NRAS, and KIT was per-
formed on the same tumors (Table 2), which were ana-
lyzed by immunohistochemistry. BRAF mutations were
detected in five patients, NRAS mutations were detected
in two patients, and wild-type BRAF and NRAS genes
were found in one patient. There was no difference in the
BRAF, NRAS, or KIT mutation status in matched cerebral
and extracerebral melanoma metastases, with one excep-
tion. In that patient, we detected wild-type BRAF and
NRAS in the brain metastasis and the BRAFV600E muta-
tion and wild-type NRAS in the matched liver metastasis.
In vitro studies
AKT is activated in monolayer cultures established
from brain and extracerebral melanoma
metastases
We also determined the expression of ERK, p-ERK, AKT,
p-AKT, and PTEN in vitro in monolayer cultures of
established matched cerebral and extracerebral metastatic
melanoma cell lines (Z€uMel1H, Z€uMel1, Z€uMel2H,
Z€uMel2). Furthermore, we determined ERK, p-ERK,
AKT, p-AKT, and PTEN expression in melanoma cells
newly isolated from brain and extracerebral distant metas-
A B
C
E F G H
D
Figure 3. (A–E) Brain and lung metastases from a melanoma patient were stained to detect the melanocytic marker Melan A, total and activated
ERK (p-ERK), total and activated AKT (p-AKT), and PTEN; 409: 40-fold magnification, 2009: 200-fold magnification. (F) Brain metastasis from a
melanoma patient was stained for p-AKT (red) and HMB-45 (brown) to detect melanoma cells, 2009: 200-fold magnification. The insert shows
colocalization of p-AKT (red) with HMB-45 (brown), 630-fold magnification. (G) Brain metastasis from a melanoma patient was stained for p-AKT
(red) and glial fibrillary acidic protein (GFAP) (brown) to detect glial cells, 2009: 200-fold magnification. GFAP does not colocalize with
p-AKT. (H) Brain metastasis from a melanoma patient was stained for p-AKT (red) and CD14 (brown) to detect monocytes/macrophages, 2009:
200-fold magnification. CD14 does not colocalize with p-AKT.
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tases of melanoma patients (T€uMel32H, T€uMel32;
T€uMel19H, T€uMel21H, T€uMel25H; T€uMel22, T€uMel23,
T€uMel27, T€uMel28, T€uMel30). In contrast to the immu-
nohistochemical findings in the tumor tissues described
above, there was no difference in AKT activation or
PTEN expression status in brain and extracerebral meta-
static melanoma cells from the monolayer cultures
(Table 3). AKT, p-AKT, and PTEN were clearly expressed
in both the established and the newly isolated cerebral
and matched extracerebral metastatic melanoma cell lines
with one exception showing loss of PTEN in cells isolated
from a melanoma brain metastasis (Table 3).
Astrocyte-conditioned medium stimulates AKT
activation and invasiveness in melanoma cells
To further investigate the differences in the findings in tumor
tissues and tumor cell lines, cerebral and matched extra-
cerebral metastatic melanoma cells were stimulated by two
kinds of conditioned media. First, to simulate the tumor
environment of brain metastases, melanoma cells were stimu-
lated by astrocyte-conditioned medium. Second, to simulate
the tumor environment of extracerebral metastases, cells were
stimulated by fibroblast-conditioned medium. Melanoma
cells grown in culture medium served as controls. Most inter-
estingly, both cerebral and matched extracerebral metastatic
melanoma cells stimulated by astrocyte-conditioned medium
showed a higher activation of AKT (p-AKT) than cells stimu-
lated by fibroblast-conditioned medium (Fig. 4A).
To evaluate the invasive competence of melanoma cells
in response to stimulation by astrocyte-conditioned med-
ium, a transwell matrigel invasion assay was employed.
Astrocyte-conditioned medium strongly increased inva-
siveness of melanoma cells compared with fibroblast-
conditioned medium or serum-free medium (Fig. 4B and C).
PI3K inhibition sensitizes melanoma cells isolated
from a vemurafenib-resistant brain metastasis to
vemurafenib
To study the effects of PI3K inhibition on vemurafenib-
resistant brain metastatic melanoma cells, we isolated
Table 1. Expression and activation of ERK, AKT, and PTEN in cerebral
and matched extracerebral melanoma metastases.
Patient
sample
Melanoma
metastases ERK p-ERK AKT p-AKT PTEN
1 Brain +++ ++ +++ +++ 
Lung +++ + +++  ++
2 Brain +++ + +++ ++ 
Lymph node ++ + +  NA
3 Brain ++ + + +++ 
Lymph node ++ + ++  +
4 Brain +++ + +++ ++ 
Lymph node +++ ++ +++  +
5 Brain +++ ++ ++  +
Skin +++ ++ +++  +
6 Brain +++ ++ +++ +++ +
Lung +++ + +++  NA
7 Brain NA NA NA +++ NA
Liver +    NA
8 Brain NA NA NA +++ NA
Intestine +++ + ++ + NA
9 Brain +++ ++ ++ +++ 
Intestine ++ + + + 
, <10% of the cells positive; +, 10–20% of cells positive; ++, 20–
50% of cells positive; +++, >50% of cells positive; NA, not available.
Table 2. Mutational analysis of cerebral and matched extracerebral
melanoma metastases.
Patient sample Melanoma metastases BRAF NRAS KIT
1 Brain V600K WT WT
Lung V600K WT WT
2 Brain V600E WT WT
Lymph node V600E WT WT
3 Brain WT Q61R WT
Lymph node WT Q61R WT
4 Brain V600E WT WT
Lymph node V600E WT WT
5 Brain WT Q61H WT
Skin WT Q61H WT
6 Brain V600K WT WT
Lung V600K WT WT
7 Brain WT WT WT
Liver V600E WT WT
8 Brain V600K WT WT
Intestine V600K WT WT
9 Brain V600R WT WT
Intestine V600R WT WT
Table 3. Expression and activation of AKT and PTEN in cerebral and
extracerebral metastatic melanoma cell lines by Western blot analysis.
AKT p-AKT PTEN
Z€uMel1H ++ + +
Z€uMel1 ++ + +
Z€uMel2H ++ ++ +
Z€uMel2 ++ ++ +
T€uMel32H ++ + +
T€uMel32 ++ + +
T€uMel19H ++ + 
T€uMel21H ++ + ++
T€uMel25H ++ + ++
T€uMel22 ++ + +
T€uMel23 ++ + +
T€uMel27 ++ + ++
T€uMel28 ++ + +
T€uMel30 ++ + +
H, cerebral; +, expressed; ++, highly expressed.
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Figure 4. (A) Melanoma cells derived from patients with extracerebral metastases (Z€uMel1, T€uMel32) and matched brain metastases (Z€uMel1H,
T€uMel32H) were treated with culture medium without serum as control (ctrl), fibroblast- or astrocyte-conditioned media (cm). The expression of
total and activated AKT (p-AKT) and b-actin was analyzed by Western blot analysis. The bottom row shows quantification of p-AKT levels. One
representative experiment is shown (three independent experiments). (B) Melanoma cells derived from a patient with extracerebral (Z€uMel1) and
matched brain (Z€uMel1H) metastases were subjected to a transwell matrigel invasion assay. The lower chamber of the transwell was filled with
serum-free culture medium (ctrl), fibroblast- or astrocyte-conditioned medium (cm). Arrows indicate melanoma cells that invaded through the
Matrigel matrix. (C) Quantification of transwell matrigel invasion assay. The number of melanoma cells invaded through the Matrigel matrix is
expressed as fold change compared with the control (ctrl, Z€uMel1, serum-free medium). One representative experiment is shown (mean  SD of
duplicates, three independent experiments). (D) Growth assessment (4-methylumbelliferyl heptanoate) of vemurafenib-resistant brain metastatic
melanoma cells treated with the indicated concentrations of the BRAF inhibitor vemurafenib or/and the PI3K inhibitor GDC0941 for 72 h. The
percentage of growth inhibition was compared to DMSO-treated controls. One representative experiment is shown (mean  SD, three
independent experiments). (E) Vemurafenib-resistant brain metastatic melanoma cells were treated with the BRAF inhibitor vemurafenib or/and
the PI3K inhibitor GDC0941, or DMSO (control) for 72 h. Apoptosis (<G1, subG1 fraction) was quantified by propidium iodide staining. One
representative experiment is shown (three independent experiments).
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melanoma cells from a brain metastasis in a patient who
was treated with vemurafenib and had a complete remis-
sion of extracerebral metastases, but developed a new
brain metastasis. Treatment of vemurafenib-resistant
brain metastatic melanoma cells with vemurafenib
resulted in marginal growth inhibition and apoptosis
induction (Fig. 4D and E). Most importantly, combining
vemurafenib with the PI3K inhibitor GDC-0941 at equi-
molar concentrations augmented growth inhibition in
these cells (Fig. 4D). Moreover, vemurafenib combined
with GDC-0941 induced significant apoptosis in vemu-
rafenib-resistant brain metastatic melanoma cells
(Fig. 4E).
Discussion
In metastatic melanoma, brain metastases occur in the
majority of patients and are the most common cause of
death. Ongoing clinical studies suggest limited activity of
BRAF inhibitors in melanoma brain metastases. We
observed in a subset of patients that vemurafenib yielded
a partial or complete response in extracerebral metastases,
but brain metastases developed. Our immunohisto-
chemical analysis of matched brain and extracerebral
metastases demonstrated high AKT activation and loss of
PTEN expression in most brain metastases. Astrocyte-
conditioned medium stimulated AKT activation and inva-
siveness in melanoma cells, and inhibition of PI3K-AKT
signaling sensitized melanoma cells isolated from a vemu-
rafenib-resistant brain metastasis to vemurafenib. Collec-
tively, these data suggest that brain-derived factors induce
activation of the AKT survival pathway and promote the
survival and drug resistance of melanoma cells in the
brain.
In a series of patients with metastatic melanoma, we
observed a difference in the treatment responses of mela-
noma patients to targeted therapy with vemurafenib:
there was partial or complete remission of extracerebral
metastases, but development of new cerebral metastases.
Many traditional chemotherapeutic agents, as well as
newer targeted drugs such as trastuzumab, cannot effi-
ciently cross the blood–brain barrier. The brain is thus
regarded as a sanctuary site for metastatic tumor cells,
affording them protection from anticancer drugs. Indeed,
recent in vitro studies demonstrated that vemurafenib is a
substrate for the efflux transporters P-glycoprotein (P-gp)
and breast cancer-resistance protein (BCRP) [16]. Further-
more, in vivo studies in mice showed that P-gp and
BCRP cooperatively restrict the brain distribution of
vemurafenib [16], and that coadministration of the P-gp
and BCRP inhibitor elacridar increases the brain penetra-
tion of vemurafenib [17]. These experimental data suggest
that vemurafenib may reach the brain at subtherapeutic
levels. However, magnetic resonance imaging shows
uptake of gadolinium contrast dye in melanoma brain
metastases and the BRAF inhibitors vemurafenib and dab-
rafenib show clinical activity, albeit limited, in melanoma
patients with brain metastases [10, 11], suggesting leakage
of the blood–brain barrier in melanoma brain metastases.
Altogether, these observations suggest that brain metasta-
ses are supported by blood–brain barrier efflux transport-
ers plus factors other than the blood–brain barrier [18,
19].
In this study, we observed a patient under treatment
with vemurafenib who experienced complete remission of
extracerebral metastases while developing a new brain
metastasis. This patient benefited when the brain meta-
stasis was excised and vemurafenib treatment was contin-
ued. In contrast, a patient who experienced complete
remission of extracerebral metastases but developed two
small brain metastases which progressed rapidly when
vemurafenib was discontinued. These observations support
the notion that patients with progressive disease at an iso-
lated site that is addressed by localized therapy may have a
survival benefit when vemurafenib is continued [20].
Immunohistochemical analysis of matched brain and
extracerebral metastases demonstrated AKT hyperactiva-
tion in brain metastases. This observation is in line with a
recently published quantitative analysis of AKT activation
in melanoma specimens and cell lines using the reverse-
phase protein array technology [21]. In the small panel of
unmatched distant metastases included in this study,
brain metastases were found to have a higher p-AKT
expression than distant metastases from the lung and
liver. In melanoma, activation of the PI3K-AKT signaling
pathway can occur through multiple mechanisms. Various
growth factors as well as adhesion molecules may result
in activation of this pathway [2, 22], AKT, that is the
AKT3 isoform, may be overexpressed as a result of copy
number increases [23], and the negative regulator of the
PI3K-AKT pathway, PTEN, may be inactivated [22].
Indeed, our immunohistochemical analysis showed that
metastases with high p-AKT, that is brain metastases, had
low PTEN levels. This observation is in line with the
above-mentioned study reporting low PTEN and elevated
p-AKT levels in brain metastases [21], and suggests that
the brain environment suppresses PTEN expression lead-
ing to high AKT activation in melanoma cells. Further-
more, BRAF-mutant metastases and cell lines were
reported to have higher p-AKT levels than NRAS-mutant
metastases and cell lines [21]. However, our mutation
analysis revealed no difference in BRAF, NRAS, or KIT
mutation status in matched brain and extracerebral
metastases of melanoma patients, indicating that hyper-
activation of AKT in melanoma brain metastases does not
depend on the mutation status of these genes.
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In monolayer cultures of brain and extracerebral meta-
static cell lines newly derived from melanoma patients,
AKT activation and PTEN expression was identical. Further-
more, melanoma cells stimulated by astrocyte-
conditioned medium showed higher activation of AKT
compared with melanoma cells stimulated by fibroblast-
conditioned medium. Astrocyte-conditioned medium
increased invasiveness of melanoma cells suggesting that
astrocyte-induced AKT activation in melanoma cells pro-
motes invasion of melanoma cells in the brain. However,
astrocytes may also contribute to the invasiveness of
tumor cells in the brain by producing enzymes such as
heparanase that degrade components of the extracellular
matrix of the brain [24]. These in vitro data, together
with the in vivo observations described above, strengthen
the hypothesis that hyperactivation of AKT in melanoma
brain metastases is due to the tumor environment.
Interestingly, competitive cross-species hybridization of
microarray experiments showed that the brain micro-
environment induces complete reprogramming of metas-
tasized cancer cells [25]. When xenografted in the brain,
all human cancer cell lines tested in this study acquired
neuronal expression patterns that can also be induced by
culture with astrocytes. When metastatic tumor cells cross
the blood–brain barrier, astrocytes are among the first
cells to interact with the brain-invading cells. Several
experimental studies indicate that astrocytes may contrib-
ute to tumor progression in the brain through a variety
of different mechanisms, including the secretion of sub-
stances that promote tumor cell proliferation and inva-
sion, protection of tumor cells from apoptosis through
direct cell–cell interactions, and suppression of adaptive
immune responses [18, 24]. Specifically, insulin-like
growth factor 1 (IGF-1), transforming growth factor beta
(TGF-b), and interleukin 6 (IL-6) secreted by astrocytes
have been shown to promote proliferation of tumor cells
in the brain [26, 27]. Thus, astrocyte-derived factors may
suppress PTEN expression, activate the AKT survival
pathway and promote treatment resistance in melanoma
cells in the brain.
Notably, inhibition of PI3K-AKT signaling resensitized
melanoma cells isolated from a vemurafenib-resistant
brain metastasis to vemurafenib. This observation suggests
that the resistance of BRAFV600E-mutated melanoma
brain metastases to vemurafenib may be overcome by
adding a PI3K inhibitor.
Taken together, our findings suggest that hyperactiva-
tion of the AKT survival pathway in melanoma brain
metastases is induced by brain-derived factors that pro-
mote the survival and drug resistance of melanoma cells
in the brain parenchyma. Inhibition of this pathway may
be a suitable strategy for enhancing and/or prolonging the
antitumor effects of BRAF inhibitors or other anticancer
agents in melanoma brain metastases. This hypothesis
should prompt experimental studies that analyze the
mechanisms of AKT activation in melanoma brain metas-
tases and clinical studies that investigate combinations of
PI3K/AKT inhibitors with BRAF/MEK inhibitors or other
anticancer agents for treatment of melanoma brain metas-
tases.
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